Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl J Fichtenbaum

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Current Infectious Disease Reports|December 20, 2008
Metabolic abnormalities associated with HIV infection and antiretroviral therapyCarl J Fichtenbaum
The AIDS Reader|July 1, 2008
Editorial comment: the head bone is connected to the body boneCarl J Fichtenbaum
HIV Clinical Trials|February 1, 2005
Coronary heart disease risk, dyslipidemia, and management in HIV-infected personsCarl J Fichtenbaum
AIDS Clinical Care|August 30, 2003
Antiretrovirals and cardiovascular disease: is HAART bad for your heart?Carl J Fichtenbaum
Current HIV/AIDS Reports|April 29, 2010
Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?Carl J Fichtenbaum
Current Infectious Disease Reports|February 11, 2011
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV InfectionCarl J Fichtenbaum
AIDS (London, England)|January 25, 2023
Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?Carl J Fichtenbaum, Patrick Mallon
Expert Opinion on Pharmacotherapy|June 25, 2019
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infectionAnna Gebhardt, Carl J Fichtenbaum
Expert Opinion on Drug Metabolism & Toxicology|July 8, 2010
Fenofibrate in the treatment of dyslipidemia associated with HIV infectionDivya Samineni, Carl J Fichtenbaum
AIDS (London, England)|December 22, 2021
Is it time to retire efavirenz as a first-line option worldwide?Juan V Guanira, Carl J Fichtenbaum
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Current Infectious Disease Reports|December 20, 2008
Metabolic abnormalities associated with HIV infection and antiretroviral therapyCarl J Fichtenbaum
The AIDS Reader|July 1, 2008
Editorial comment: the head bone is connected to the body boneCarl J Fichtenbaum
HIV Clinical Trials|February 1, 2005
Coronary heart disease risk, dyslipidemia, and management in HIV-infected personsCarl J Fichtenbaum
AIDS Clinical Care|August 30, 2003
Antiretrovirals and cardiovascular disease: is HAART bad for your heart?Carl J Fichtenbaum
Current HIV/AIDS Reports|April 29, 2010
Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?Carl J Fichtenbaum
Current Infectious Disease Reports|February 11, 2011
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV InfectionCarl J Fichtenbaum
AIDS (London, England)|January 25, 2023
Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?Carl J Fichtenbaum, Patrick Mallon
Expert Opinion on Pharmacotherapy|June 25, 2019
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infectionAnna Gebhardt, Carl J Fichtenbaum
Expert Opinion on Drug Metabolism & Toxicology|July 8, 2010
Fenofibrate in the treatment of dyslipidemia associated with HIV infectionDivya Samineni, Carl J Fichtenbaum
AIDS (London, England)|December 22, 2021
Is it time to retire efavirenz as a first-line option worldwide?Juan V Guanira, Carl J Fichtenbaum
Pageof 17